CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Tamara L. Joseph as Senior Vice President, General Counsel and Chief Compliance Officer, effective March 24, 2014. Ms. Joseph comes to InVivo with extensive leadership experience in the biotechnology and pharmaceutical industries as a result of holding senior positions in the US and Europe over the past 16 years.
"I am confident that Tamara's judgment, strategic mindset, and integrity will be important assets for InVivo. We are proud to have attracted another experienced health care executive to help the company achieve its vision of bringing groundbreaking technologies to underserved patient populations."
Mark Perrin, InVivo's Chief Executive Officer said, "I am confident that Tamara's judgment, strategic mindset, and integrity will be important assets for InVivo. We are proud to have attracted another experienced health care executive to help the company achieve its vision of bringing groundbreaking technologies to underserved patient populations."
Ms. Joseph is a seasoned public company General Counsel, with broad global experience in the development and commercialization of products in various therapeutic areas. She previously served as Senior Vice President, General Counsel of Cubist Pharmaceuticals, Inc., where she was responsible for the law, compliance, risk management and government affairs departments. Prior to that, she served as Executive Vice President, General Counsel of Mayne Pharma Ltd., and prepared that company for listing on the London Stock Exchange and advised the Board regarding Mayne's acquisition by Hospira, Inc. Before that she served at Transkaryotic Therapies, Inc. as Vice President, General Counsel during the negotiations with Shire Pharmaceuticals Group plc and through that company's acquisition by Shire. From 1998-2005, Ms. Joseph led the Biogen Idec legal department's operations outside the United States as Vice President, International Legal. Ms. Joseph began her legal career as a litigator with Fried, Frank, Harris, Shriver & Jacobson in New York City and later at Morrison & Foerster in Los Angeles, New York and Brussels. Ms. Joseph has an AB in Economics from Duke University, a JD from University of Michigan Law School, an LLM degree in European Community Law from the College of Europe in Belgium and an LLM degree in Civil Law from the University of Paris. She is a member of the bar in New York, California, England and Wales. Ms. Joseph is also an independent director and the incoming Vice Chair at PHFE, a non-profit public health organization. She currently serves as Vice Chair of PHFE's Audit Committee and is a member of its Governance and Nominating Committee.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries. The Company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, and include statements regarding the Company's expectations with respect to achieving groundbreaking technologies. These statements are subject to a number of risks and uncertainties that could cause actual future results to differ materially from current expectations including, but not limited to, risks and uncertainties relating to the Company's limited operating history and history of net losses, its ability to raise substantial additional capital to finance planned operations, its ability to successfully commercialize current and future product candidates and to successfully complete clinical trials and obtain and maintain regulatory approval of its product candidates, its ability to protect and maintain its intellectual property, and other risks associated with the Company's business and strategies identified and described in more detail in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings with the Securities and Exchange Commission. We do not undertake to update these forward-looking statements made by us.
Brian Luque, 617-863-5535